Responses to CAR T-Cell therapy still strong after one year in patients with refractory NHL
Ibrutinib and FCR chemoimmunotherapy: improving complete remission in CLL patients?
Venetoclax combination studies showing great promise at ASH 2017
Collaboration and cooperation in hematology-oncology research
How to generate an anticancer immune response in multiple myeloma